Anemia, including all-grade (3.84%) and grade III or higher (0.74%) anemia, is the most common hematologic adverse event of PD-1 and PD-L1 inhibitors in advanced-stage cancer [98]. This evidence concerns the gene CD274 and anemia (phenotype).